Bharat Biotech snaps up GSK rabies unit


Global pharmaceutical giant GlaxoSmithKline’s (GSK) sale of its Gujarat-based anti-rabies vaccine arm Chiron Behring Vaccines to Bharat Biotech International was a complex deal given the regulated nature of the vaccines.

“Unlike regular vaccines, anti-rabies vaccines are not preventative and are regulated both in India as well as in many jurisdictions around the world,” Talwar Thakore & Associates partner Feroz Dubash told India Business Law Journal.

“Negotiating non-compete arrangements in specific territories had to take the regulations into account. In a number of jurisdictions, regulators could insist on stocks of the vaccine being available. Additionally, quality arrangements are vital, both as a public health matter and from a liability perspective.”

You must be a subscribersubscribersubscribersubscriber to read this content, please subscribesubscribesubscribesubscribe today.

For group subscribers, please click here to access.
Interested in group subscription? Please contact us.